Floatz Rating
B60/100
Confidence
Indicative
Sponsor
SWOG Cancer Research Network
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03678025CT.gov Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hypogonadism
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bicalutamide (this asset) | SWOG Cancer Research Network | P3 | B · 60 |
| Carboplatin | University of Washington | P2 | BB |
| Testosterone Undecylate | Royal College of Surgeons, Ireland | P3 | BB |
| Prednisone | SWOG Cancer Research Network | P3 | BB |
| Docetaxel | SWOG Cancer Research Network | P3 | BB |
| Abiraterone | SWOG Cancer Research Network | P3 | BB |
| Semaglutide | University Medical Centre Ljubljana | P3 | BB |
| Pembrolizumab | University of California, San Francisco | P2 | B |
| Enzalutamide | Roswell Park Cancer Institute | P1/2 | B |
+27 more in the Hypogonadism cohort
Other indications for Bicalutamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Adenocarcinoma | — | P3 | BB · 69 |
| Triple-Negative Breast Carcinoma | — | P3 | BB · 67 |
| Prostate Cancer | — | P4 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bicalutamide in Hypogonadism. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bicalutamide-hypogonadism
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →